No One-Size-Fits-All Solution for Autologous Cell Therapy Manufacturing

The article focuses on the operational challenges inherent in producing patient-specific, autologous cell therapies, where each batch is derived from an individual patient rather than a standardized donor or cell line. These individualized workflows create complexity across collection, transport, manufacturing, and return of the finished product to the patient.

Its central argument is that no single manufacturing model works for every program. Instead, sponsors should deliberately select the approach that fits the healthcare infrastructure, logistical requirements, and market environment of the specific project at hand, rather than adopting a one-size-fits-all template.